-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] On March 16, BeiGene announced that it has completed the license introduction transaction for five Novartis anti-tumor products, namely dabrafenib, trametinib, pazopanib, Everolimus and Ceritinib have both been approved and included in the National Medical Insurance Drug List
.
Among them, dabrafenib is a BRAF inhibitor, trametinib is a MEK inhibitor; pazopanib is a VEGFR inhibitor; everolimus is an mTOR inhibitor; ceritinib is an ALK inhibitor
.
On March 16, BeiGene announced that it has completed the licensing and introduction of these five Novartis anti-tumor products, and will conduct marketing, promotion and sales in designated areas within China (referred to as the "broad market")
.
Data shows that China's "broad market" includes about 13,000 hospitals in cities and districts and counties, covering about 500,000 cancer patients
.
The products independently developed and authorized by BeiGene have a high market share in these regions
.
The data shows that in 2020, the total sales volume of the above five products in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers and China's urban physical pharmacy terminals has exceeded 1 billion yuan
.
Through this cooperation, BeiGene's product pipeline will be expanded again
.
It is understood that BeiGene currently has 16 approved anti-tumor drugs in China.
The company relies on self-developed products and authorized introduction of products to increase sales.
In 2021, annual product sales will increase by 105.
3%, about 4 billion Yuan
.
In addition, according to data, BeiGene's operating income for the whole year of 2021 increased by 281% year-on-year, or approximately RMB 7.
6 billion
.
For the development of BeiGene, the industry said that innovation and R&D have brought huge impetus to the company
.
Data show that in 2021, BeiGene's annual R&D expenses will increase by 15% year-on-year, or about 9.
5 billion yuan
.
It is precisely because of its strong R&D capabilities and product advantages that BeiGene can continuously attract the favor of multinational pharmaceutical companies and bring them a large amount of cooperation income
.
For example, in January and December 2021, BeiGene reached a global development and commercialization cooperation with Novartis on Baizean® and the TIGIT inhibitor osperimab, respectively.
The potential total potential brought by the two record global cooperation The total transaction value will exceed 5 billion US dollars
.
BeiGene has established key capabilities for internal implementation of global clinical operations and drug administration declarations through its extensive global deployment.
It can not only independently and efficiently promote large-scale global clinical trials, but also support the company's international clinical trials.
Data declarations around the world improve the approval efficiency and success rate
.
Data shows that by the end of 2021, BeiGene's global commercialization team has about 3,400 people, including teams in Europe and the United States.
In China, the commercialization team covers more than 1,000 hospitals
.
The Guangzhou factory has an approved production capacity of 8,000 liters.
It is expected to reach 64,000 liters by the end of this year.
The long-term planned production capacity exceeds 120,000 liters, and it can reach 200,000 liters
.
Suzhou Small Molecule Innovative Drug Industrialization Base, the first-stage solid preparation production capacity can reach 600 million tablets (granules), and it is expected to be completed in 2023, which can increase the production capacity of small molecule drugs to 6 times the current level
.
The production and R&D base in New Jersey, USA will start construction this year, covering an area of 170,000 square meters, laying the foundation for the production capacity of the US market
.
93,000 square meters of developable real estate are reserved for future expansion
.
The cooperation between BeiGene and Novartis to introduce 5 anti-tumor products will further expand its product pipeline and achieve further development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, dabrafenib is a BRAF inhibitor, trametinib is a MEK inhibitor; pazopanib is a VEGFR inhibitor; everolimus is an mTOR inhibitor; ceritinib is an ALK inhibitor
.
On March 16, BeiGene announced that it has completed the licensing and introduction of these five Novartis anti-tumor products, and will conduct marketing, promotion and sales in designated areas within China (referred to as the "broad market")
.
Data shows that China's "broad market" includes about 13,000 hospitals in cities and districts and counties, covering about 500,000 cancer patients
.
The products independently developed and authorized by BeiGene have a high market share in these regions
.
The data shows that in 2020, the total sales volume of the above five products in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers and China's urban physical pharmacy terminals has exceeded 1 billion yuan
.
Through this cooperation, BeiGene's product pipeline will be expanded again
.
It is understood that BeiGene currently has 16 approved anti-tumor drugs in China.
The company relies on self-developed products and authorized introduction of products to increase sales.
In 2021, annual product sales will increase by 105.
3%, about 4 billion Yuan
.
In addition, according to data, BeiGene's operating income for the whole year of 2021 increased by 281% year-on-year, or approximately RMB 7.
6 billion
.
For the development of BeiGene, the industry said that innovation and R&D have brought huge impetus to the company
.
Data show that in 2021, BeiGene's annual R&D expenses will increase by 15% year-on-year, or about 9.
5 billion yuan
.
It is precisely because of its strong R&D capabilities and product advantages that BeiGene can continuously attract the favor of multinational pharmaceutical companies and bring them a large amount of cooperation income
.
For example, in January and December 2021, BeiGene reached a global development and commercialization cooperation with Novartis on Baizean® and the TIGIT inhibitor osperimab, respectively.
The potential total potential brought by the two record global cooperation The total transaction value will exceed 5 billion US dollars
.
BeiGene has established key capabilities for internal implementation of global clinical operations and drug administration declarations through its extensive global deployment.
It can not only independently and efficiently promote large-scale global clinical trials, but also support the company's international clinical trials.
Data declarations around the world improve the approval efficiency and success rate
.
Data shows that by the end of 2021, BeiGene's global commercialization team has about 3,400 people, including teams in Europe and the United States.
In China, the commercialization team covers more than 1,000 hospitals
.
The Guangzhou factory has an approved production capacity of 8,000 liters.
It is expected to reach 64,000 liters by the end of this year.
The long-term planned production capacity exceeds 120,000 liters, and it can reach 200,000 liters
.
Suzhou Small Molecule Innovative Drug Industrialization Base, the first-stage solid preparation production capacity can reach 600 million tablets (granules), and it is expected to be completed in 2023, which can increase the production capacity of small molecule drugs to 6 times the current level
.
The production and R&D base in New Jersey, USA will start construction this year, covering an area of 170,000 square meters, laying the foundation for the production capacity of the US market
.
93,000 square meters of developable real estate are reserved for future expansion
.
The cooperation between BeiGene and Novartis to introduce 5 anti-tumor products will further expand its product pipeline and achieve further development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
